Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Its distinct advantage over current jabs is that it would only have to be injected once a month, as opposed to once a week ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised multidisciplinary treatments, at a cost.

A nurse has warned about a common Mounjaro ‘mistake’ that can increase people’s risk of deadly organ damage.